Project Details
Description
A Phase 2, randomized, partially blinded, controlled, dose-ranging study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of VEL-101 in kidney transplant recipients.
| Status | Active |
|---|---|
| Effective start/end date | 9/23/25 → 9/22/35 |
Funding
- VELOXIS PHARMACEUTICALS A/S
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.